Why Abzena?
Our focused approach.
Vice Presidents of Business Development Sudha Krishnan and Zoe Yi Zhang welcome the opportunity to schedule some time to connect on your project-specific needs and to provide you with an update on our expanded global capabilities.
From antibodies (mAbs) to recombinant vaccines and bioconjugates including antibody-drug conjugates (ADCs), radioconjugates, and oligonucleotides, our team appreciates the chance to share how Abzena can assist in moving your program forward faster to its next milestone.
For more event information: Home – 16th Drug Discovery Strategic Summit (agilefalconsg.com)